Idebenone

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Friedreich's Ataxia

Conditions

Friedreich's Ataxia

Trial Timeline

Jul 1, 2008 → May 1, 2010

NCT ID

NCT00697073

About Idebenone

Idebenone is a phase 3 stage product being developed by Santhera Pharmaceuticals for Friedreich's Ataxia. The current trial status is completed. This product is registered under clinical trial identifier NCT00697073. Target conditions include Friedreich's Ataxia.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03433807	Pre-clinical	Completed	—	—	Duchenne Muscular Dystrophy
NCT02771379	Pre-clinical	Completed	Sep 1, 2016	Apr 16, 2021	Leber's Hereditary Optic Neuropathy (LHON)
NCT02774005	Approved	Completed	May 1, 2016	Mar 29, 2021	Leber's Hereditary Optic Neuropathy (LHON)
NCT00758225	Phase 2	Completed	Sep 1, 2008	Jan 1, 2011	Duchenne Muscular Dystrophy
NCT00697073	Phase 3	Completed	Jul 1, 2008	May 1, 2010	Friedreich's Ataxia
NCT00993967	Phase 3	Completed	Jun 1, 2007	Jun 1, 2012	Freidreich's Ataxia

Competing Products

11 competing products in Friedreich's Ataxia

See all competitors

Product	Company	Stage	Hype Score
Interferon γ-1b	Amgen	Phase 3	76
interferon γ-1b	Amgen	Phase 3	76
Interferon γ-1b + Placebo	Amgen	Phase 3	76
varenicline + placebo	Pfizer	Phase 2/3	64
Lu AA24493 + Placebo	Lundbeck	Phase 2	49
Omeveloxolone	Biogen	Pre-clinical	20
Placebo + EPI-743 400 mg + EPI-743 200 mg	PTC Therapeutics	Phase 2	49
SGT-212	Solid Biosciences	Phase 1	25
idebenone + Placebo	Santhera Pharmaceuticals	Phase 3	69
Idebenone + Idebenone + Placebo	Santhera Pharmaceuticals	Phase 3	69
Idebenone + Placebo	Santhera Pharmaceuticals	Phase 3	69

Other Products from Santhera Pharmaceuticals

vamorolone 40 mg/mL oral suspensionApproved

IdebenoneApproved

Placebo + IdebenonePhase 3

idebenonePhase 3

idebenone + PlaceboPhase 3